New treatment for joint damage after injuries
Engineered Biotherapeutic Agent for Treatment of Post-Traumatic Osteoarthritis
This study is testing a new injectable treatment called HydroGEN for people with post-traumatic osteoarthritis, which can happen after joint injuries like ACL tears, to help reduce pain and inflammation while supporting cartilage healing.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Provizigen LLC NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11259928 on NIH RePORTER |
What this research studies
This research focuses on developing a novel injectable hydrogel treatment for post-traumatic osteoarthritis (PTOA), a condition that arises after joint injuries like ACL tears. The hydrogel, named HydroGEN, is designed to deliver anti-inflammatory and cartilage-protecting molecules directly into the joint space, aiming to reduce pain and inflammation while promoting cartilage repair. The approach has shown promising results in preclinical models, suggesting it could significantly alter the course of PTOA if successful.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have experienced acute joint injuries, particularly those involving the anterior cruciate ligament (ACL), and are at risk of developing post-traumatic osteoarthritis.
Not a fit: Patients with chronic osteoarthritis not related to acute joint injuries may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that slows or prevents the progression of post-traumatic osteoarthritis, potentially reducing the need for joint replacement surgeries.
How similar studies have performed: Other research has shown success with similar injectable therapies in managing joint conditions, indicating that this approach has potential based on prior findings.
Where this research is happening
New York, United States
- Provizigen LLC — New York, United States (Active)
Researchers
- Principal investigator: Chaugule, Jui Shivaji — Provizigen LLC
- Study coordinator: Chaugule, Jui Shivaji
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.